Literature DB >> 21525393

The immunosuppressive role of IL-32 in lymphatic tissue during HIV-1 infection.

Anthony J Smith1, Chad M Toledo, Stephen W Wietgrefe, Lijie Duan, Timothy W Schacker, Cavan S Reilly, Ashley T Haase.   

Abstract

One pathological hallmark of HIV-1 infection is chronic activation of the immune system, driven, in part, by increased expression of proinflammatory cytokines. The host attempts to counterbalance this prolonged immune activation through compensatory mediators of immune suppression. We recently identified a gene encoding the proinflammatory cytokine IL-32 in microarray studies of HIV-1 infection in lymphatic tissue (LT) and show in this study that increased expression of IL-32 in both gut and LT of HIV-1-infected individuals may have a heretofore unappreciated role as a mediator of immune suppression. We show that: 1) IL-32 expression is increased in CD4(+) T cells, B cells, macrophages, dendritic cells, and epithelial cells in vivo; 2) IL-32 induces the expression of immunosuppressive molecules IDO and Ig-like transcript 4 in immune cells in vitro; and 3) in vivo, IL-32-associated IDO/Ig-like transcript 4 expression in LT macrophages and gut epithelial cells decreases immune activation but also may impair host defenses, supporting productive viral replication, thereby accounting for the correlation between IL-32 levels and HIV-1 replication in LT. Thus, during HIV-1 infection, we propose that IL-32 moderates chronic immune activation to avert associated immunopathology but at the same time dampens the antiviral immune response and thus paradoxically supports HIV-1 replication and viral persistence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21525393      PMCID: PMC3098930          DOI: 10.4049/jimmunol.1100277

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

Review 1.  Immune inhibitory receptors.

Authors:  J V Ravetch; L L Lanier
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

2.  CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques.

Authors:  Anna Hryniewicz; Adriano Boasso; Yvette Edghill-Smith; Monica Vaccari; Dietmar Fuchs; David Venzon; Janos Nacsa; Michael R Betts; Wen-Po Tsai; Jean-Michel Heraud; Brigitte Beer; Diann Blanset; Claire Chougnet; Israel Lowy; Gene M Shearer; Genoveffa Franchini
Journal:  Blood       Date:  2006-08-08       Impact factor: 22.113

Review 3.  Cellular antimicrobial immunity.

Authors:  F M Collins
Journal:  CRC Crit Rev Microbiol       Date:  1978

4.  Downregulation of immune response by the human cytokines Interleukin-32alpha and beta in cell-mediated rejection.

Authors:  Jung Il Chae; Jung Hyun Shim; Kwang Su Lee; Young Sik Cho; Kyu-Sun Lee; Do Young Yoon; Soo Hyun Kim; Hyung-Min Chung; Deog-Bon Koo; Chang-Sik Park; Dong-Seok Lee; Pyung Keun Myung
Journal:  Cell Immunol       Date:  2010-06-11       Impact factor: 4.868

5.  Interleukin-32: a cytokine and inducer of TNFalpha.

Authors:  Soo-Hyun Kim; Sun-Young Han; Tania Azam; Do-Young Yoon; Charles A Dinarello
Journal:  Immunity       Date:  2005-01       Impact factor: 31.745

6.  The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells.

Authors:  Francesca Fallarino; Ursula Grohmann; Sylvaine You; Barbara C McGrath; Douglas R Cavener; Carmine Vacca; Ciriana Orabona; Roberta Bianchi; Maria L Belladonna; Claudia Volpi; Pere Santamaria; Maria C Fioretti; Paolo Puccetti
Journal:  J Immunol       Date:  2006-06-01       Impact factor: 5.422

7.  Microarray analysis of lymphatic tissue reveals stage-specific, gene expression signatures in HIV-1 infection.

Authors:  Qingsheng Li; Anthony J Smith; Timothy W Schacker; John V Carlis; Lijie Duan; Cavan S Reilly; Ashley T Haase
Journal:  J Immunol       Date:  2009-07-13       Impact factor: 5.422

Review 8.  IDO expression by dendritic cells: tolerance and tryptophan catabolism.

Authors:  Andrew L Mellor; David H Munn
Journal:  Nat Rev Immunol       Date:  2004-10       Impact factor: 53.106

9.  Functional genomic analysis of the response of HIV-1-infected lymphatic tissue to antiretroviral therapy.

Authors:  Qingsheng Li; Timothy Schacker; John Carlis; Gregory Beilman; Phuong Nguyen; Ashley T Haase
Journal:  J Infect Dis       Date:  2004-02-05       Impact factor: 5.226

Review 10.  Putting out the fire: coordinated suppression of the innate and adaptive immune systems by SOCS1 and SOCS3 proteins.

Authors:  Ioannis D Dimitriou; Liliana Clemenza; Andrew J Scotter; Grace Chen; Fiona M Guerra; Robert Rottapel
Journal:  Immunol Rev       Date:  2008-08       Impact factor: 12.988

View more
  25 in total

Review 1.  The CD8+ T Cell Noncytotoxic Antiviral Responses.

Authors:  Maelig G Morvan; Fernando C Teque; Christopher P Locher; Jay A Levy
Journal:  Microbiol Mol Biol Rev       Date:  2021-05-12       Impact factor: 11.056

2.  Dendritic Cell-Derived IL-32α: A Novel Inhibitory Cytokine of NK Cell Function.

Authors:  Laurent Gorvel; Daniel Korenfeld; Thomas Tung; Eynav Klechevsky
Journal:  J Immunol       Date:  2017-07-12       Impact factor: 5.422

3.  Role of Interleukin 32 in Human Immunodeficiency Virus Reactivation and Its Link to Human Immunodeficiency Virus-Herpes Simplex Virus Coinfection.

Authors:  Pedro M M Mesquita; Paula Preston-Hurlburt; Marla J Keller; Nalini Vudattu; Lilia Espinoza; Michelle Altrich; Kathryn Anastos; Kevan C Herold; Betsy C Herold
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

Review 4.  Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity.

Authors:  Jamie L Harden; Nejat K Egilmez
Journal:  Immunol Invest       Date:  2012       Impact factor: 3.657

5.  Interleukin-32 isoforms: expression, interaction with interferon-regulated genes and clinical significance in chronically HIV-1-infected patients.

Authors:  Katia Monteleone; Pierluigi Di Maio; Giulia Cacciotti; Francesca Falasca; Maurizio Fraulo; Mario Falciano; Ivano Mezzaroma; Gabriella D'Ettorre; Ombretta Turriziani; Carolina Scagnolari
Journal:  Med Microbiol Immunol       Date:  2014-02-20       Impact factor: 3.402

Review 6.  Role of interleukin-32 in chronic rhinosinusitis.

Authors:  Anjeni Keswani; Robert C Kern; Robert P Schleimer; Atsushi Kato
Journal:  Curr Opin Allergy Clin Immunol       Date:  2013-02

Review 7.  Novel insights into the biology of interleukin-32.

Authors:  Leo A B Joosten; Bas Heinhuis; Mihai G Netea; Charles A Dinarello
Journal:  Cell Mol Life Sci       Date:  2013-03-06       Impact factor: 9.261

8.  Upregulation of IL-32 Isoforms in Virologically Suppressed HIV-Infected Individuals: Potential Role in Persistent Inflammation and Transcription From Stable HIV-1 Reservoirs.

Authors:  Sarah M Zaidan; Louise Leyre; Rémi Bunet; Etienne Larouche-Anctil; Isabelle Turcotte; Mohamed Sylla; Annie Chamberland; Carl Chartrand-Lefebvre; Petronela Ancuta; Jean-Pierre Routy; Jean-Guy Baril; Benoit Trottier; Paul MacPherson; Sylvie Trottier; Marianne Harris; Sharon Walmsley; Brian Conway; Alexander Wong; Réjean Thomas; Robert C Kaplan; Alan L Landay; Madeleine Durand; Nicolas Chomont; Cécile L Tremblay; Mohamed El-Far
Journal:  J Acquir Immune Defic Syndr       Date:  2019-12-15       Impact factor: 3.731

9.  Impact of intra-tumoral IL17A and IL32 gene expression on T-cell responses and lymph node status in breast cancer patients.

Authors:  Shreyas Bhat; Nilesh Gardi; Sujata Hake; Nirupama Kotian; Sharada Sawant; Sadhana Kannan; Vani Parmar; Sangeeta Desai; Amit Dutt; Narendra N Joshi
Journal:  J Cancer Res Clin Oncol       Date:  2017-05-03       Impact factor: 4.553

10.  Enhanced susceptibility to lipopolysaccharide-induced arthritis and endotoxin shock in interleukin-32 alpha transgenic mice through induction of tumor necrosis factor alpha.

Authors:  Masanori Nakayama; Yasuo Niki; Toshiki Kawasaki; Yuki Takeda; Keisuke Horiuchi; Aya Sasaki; Yasunori Okada; Kazuo Umezawa; Hiroyasu Ikegami; Yoshiaki Toyama; Takeshi Miyamoto
Journal:  Arthritis Res Ther       Date:  2012-05-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.